Infusion therapy for chronic liver diseases

Infusion therapy for chronic liver diseases

Aim of review. To present modern options of comprehensive infusion therapy at various liver diseases, indications and contraindications for application of basic blood substitute groups, and pathogenically justified approaches for their use. Summary. Chronic and acute liver diseases are associated to...

Full description

Saved in:

Bibliographic Details
Main Authors:	I. A. Kurkina, M. V. Mayevskaya, I. N. Tikhonov, V. N. Zozulya, V. I. Leschenko
Format:	Article
Language:	Russian
Published:	Gastro LLC 2018-08-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	инфузионная терапия гепатит цирроз печени альбумин янтарная кислота
Online Access:	https://www.gastro-j.ru/jour/article/view/243
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of 3D-therapy at HCV-related subcompensated liver cirrhosis (genotype 1b)
by: P. O. Bogomolov, et al.
Published: (2018-08-01)

The issue of clinical application of non-invasive evaluation of liver fibrosis at chronic hepatitis B
by: Chavdar S. Pavlov, et al.
Published: (2016-08-01)

Treatment compliance of liver cirrhosis patients
by: Ye. R. Olevskaya, et al.
Published: (2018-08-01)

The effect of Clostridium difficile infection on the course of liver cirrhosis
by: A. A. Driga, et al.
Published: (2018-08-01)

Urinary tract infections in patients with decompensated liver cirrhosis, listed for liver transplantation
by: P. D. Bessonov, et al.
Published: (2018-08-01)

Principles of diuretic therapy at liver cirrhosis
by: A. I. Dyadyk, et al.
Published: (2018-08-01)

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Liver cirrhosis epidemiology in Chelyabinsk region in 2006-2015
by: A. I. Dolgushina, et al.
Published: (2018-08-01)

Rare forms of nonalcoholic fatty liver disease: hereditary lysosomal acid lipase deficiency
by: M. V. Mayevskaya, et al.
Published: (2016-08-01)

Results of non-interventional observational study of ursodeoxycholic acid in primary biliary cirrhosis
by: Yelena N. Shirokova, et al.
Published: (2018-08-01)

Гиповолемический шок у взрослых. Клинические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов»
by: Игорь Борисович Заболотских, et al.
Published: (2024-11-01)

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience)
by: I. Yu. Pirogova, et al.
Published: (2018-08-01)

Noninvasive diagnostic methods of liver fibrosis in patients with primary biliary cirrhosis and primary sclerosing cholangitis: role of indirect serological markers
by: A. F. Sheptulina, et al.
Published: (2016-08-01)

Small intestinal bacterial overgrowth syndrome and systemic inflammation in pathogenesis of hemodynamic changes at liver cirrhosis
by: R. V. Maslennikov, et al.
Published: (2018-08-01)

The impact of bacterial overgrowth syndrome and systemic inflammation on abdominal hemodynamics in liver cirrhosis
by: R. V. Maslennikov, et al.
Published: (2018-08-01)

Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
by: M. V. Mayevskaya, et al.
Published: (2018-08-01)

Treatment compliance at initial and maintenance therapy at gastroesophageal reflux disease
by: V. I. Simanenkov, et al.
Published: (2018-08-01)

Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients
by: D. T. Abdurakhmanov, et al.
Published: (2018-08-01)

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)
by: Marina V. Mayevskaya, et al.
Published: (2018-08-01)

The role of non-alcoholic fatty liver disease in the formation of atherosclerotic vascular lesions in patients with abdominal obesity
by: N. L. Denisov, et al.
Published: (2018-08-01)

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Diagnostics and treatment of biliary dyskinesia: clinical guidelines of the Russian gastroenterological Association
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017)
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Efficacy and safety of glycyrrhizic acid and essential phospholipids (Phosphogliv) combination for alcoholic liver disease: results of the double-blind randomized placebo-controlled multicenter post-registration (phase IV) clinical trial «Jaguar» (PHG-M2/P03-12)
by: I. G. Bakulin, et al.
Published: (2018-08-01)

Options of dyslipidemia treatment at non-alcoholic fatty liver disease
by: M. V. Mayevskaya, et al.
Published: (2018-08-01)

Clinical significance of Helicobacter pylori infection in iron-deficiency anemia: features of comprehensive treatment approach
by: I. V. Mayev, et al.
Published: (2016-08-01)

Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12)
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Chronic hepatitis B and risk of kidney involvement
by: M. V. Mayevskaya, et al.
Published: (2013-05-01)

Primary liver lymphoma: review of the literature and clinical case presentation
by: A. K. Smolyaninova, et al.
Published: (2018-08-01)

Hemorrhagic syndrome at liver cirrhosis
by: I. A. Kurkina, et al.
Published: (2012-11-01)

Hypercoagulation syndrome at liver cirrhosis
by: I. A. Kurkina, et al.
Published: (2014-12-01)

Clinical presentation, diagnosis and treatment of intrahepatic cholestasis of pregnancy
by: Yu. B. Uspenskaya, et al.
Published: (2018-08-01)

Metabolism of bile acids, liver diseases and microbiome
by: Yu. V. Yevsyutina, et al.
Published: (2018-08-01)

The clinical role of blood coagulation and platelet receptors gene allelic variants in development of cryoglobulinemic vasculitis at chronic hepatitis C
by: Yekaterina Ye. Starostina, et al.
Published: (2018-08-01)

Seronegative autoimmune hepatitis
by: A. O. Buyeverov
Published: (2018-08-01)

Helicobacter pylori infection diagnostics and choice of eradication treatment: results of inquiry of doctors from different regions of Russian Federation
by: N. N. Dekhnich, et al.
Published: (2018-08-01)

Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
by: E. V. Ledin, et al.
Published: (2018-08-01)